Search Results
Sep 02, 2026, 05:03 ET What To Expect After Your Doctor Finds a Lung Nodule
greatest opportunities to improve lung cancer outcomes is the early identification and management of lung nodules, or small spots on lung imaging, that can sometimes be an early sign of lung cancer. More than half of lung nodule cases lack proper follow-up, and while most lung nodule findings do not end up
More news about: American Lung Association
Sep 01, 2026, 09:00 ET Senticell® Closes Oversubscribed Seed Round to Advance RBC-Based Liquid Biopsy Platform
patients and comparing Senticell's red-cell signal against plasma-based tests and determining tissue concordance. The company is actively enrolling 200 lung and pancreatic cancer patients at UPenn, evaluating pre-surgical driver detection and recurrence monitoring, with completion in Q1 2027. In addition,
More news about: Senticell
Sep 01, 2026, 08:00 ET New Peer-Reviewed Study Advances CIZ1B Blood Test for Early Lung Cancer Detection
Blood Test for Lung Cancer.Published Aug. 19 in The Journal of Applied Laboratory Medicine, the study, "A Molecular Tool Set for Measurement of Lung Cancer-Associated Protein Biomarker CIZ1B-FibA in Human Plasma," evaluated CIZ1B-FibA in blood plasma from patients with and without lung cancer. Led
More news about: Cizzle Bio
Sep 01, 2026, 08:00 ET Andelyn Biosciences to Scale Manufacturing for Genprex's Diabetes Gene Therapy Program
candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program
More news about: Andelyn Biosciences
Sep 01, 2026, 07:00 ET Xentria Advances XTMAB-16 Clinical Development in Pulmonary Sarcoidosis Following FDA Feedback
pulmonary sarcoidosis could degenerate into a chronic, progressive disease. Chronic, unresolved lung inflammation may result in scarring (fibrosis) that permanently damages the lung tissue and can lead to lung failure and death. In this complicated cascade of pro-inflammatory cytokines, the enhanced expression
More news about: Xentria, Inc.
Sep 01, 2026, 07:00 ET OncoC4 Appoints Dr. Steve Chen, JD, PhD as General Counsel
Treg depletion candidate targeting CTLA-4, in multiple solid tumor indications, including an ongoing pivotal clinical trial in squamous non-small cell lung cancer.For more information, please visit
More news about: OncoC4
Sep 01, 2026, 05:04 ET For Pulmonary Fibrosis Awareness Month, American Lung Association Highlights Free Program to Help People Learn to Live With PF
Lung.org/pf. About the American Lung AssociationThe American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research. The work of the American Lung Association is focused on four strategic
More news about: American Lung Association
Aug 31, 2026, 16:05 ET TransMedics to Present at Upcoming September Investor Conferences
Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences. TransMedics management is scheduled
More news about: TransMedics Group, Inc.
Aug 31, 2026, 15:10 ET Has Anyone Tried Gundry MD Vital Reds? Read Reviews, Ingredients, Benefits & More
cardiothoracic surgeons before leaving his practice to pursue restorative medicine. Today, he is the founder and medical director of The International Heart and Lung Institute and The Centers for Restorative Medicine in Palm Springs and Montecito, California, where he has spent the past 25 years helping people restore
More news about: Gundry MD
Aug 31, 2026, 09:18 ET Bitmine Immersion Technologies (BMNR) Công Bố Lượng ETH Nắm Giữ Đạt 5,90 Triệu Token, Đưa Tổng Tài Sản Tiền Mã Hóa và Tiền Mặt Lên Mức 15,6 Tỷ USD
liên kết tại đây) cho tháng 7 năm 2026. Tiêu đề của Thông Điệp này là "ETH chính là liều thuốc giải cho Thung Lũng Kỳ Lạ của Sự Giàu Có".Vào đầu năm 2026, Bitmine đã ra mắt MAVAN (Made in American VAlidator Network) – nền tảng staking chuyên biệt dành cho
More news about: Bitmine Immersion Technologies, Inc.
Aug 31, 2026, 08:22 ET CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum
observed in both the objective response rate (ORR) and duration of response (DOR):Compelling monotherapy efficacy in first-line non-small cell lung cancer (NSCLC)At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease control rate (DCR) of 100%
More news about: CStone Pharmaceuticals
Aug 31, 2026, 08:00 ET T-MAXIMUM B7-H3-Targeted Allogeneic CAR-T Therapy MT027 Receives FDA Fast Track Designation, Accelerating Global Development for Intracranial Solid Tumors
the company's prior disclosure, preliminary first-in-human data in brain metastases are planned for formal presentation during the World Conference on Lung Cancer (WCLC) in September 2026.Fast Track Designation: Added Speed for Global DevelopmentFast Track is an FDA process designed
More news about: T-MAXIMUM PHARMACEUTICAL
Aug 31, 2026, 08:00 ET Redfin Reports Americans Are Leaving Areas at Risk of Poor Air Quality, Mostly Because They're Expensive
unhealthy smoke through the Midwest and East Coast in July. It's possible air quality factors into some long-distance moves—perhaps for people with serious lung conditions—but it's unlikely to be a major factor for most Americans. Nearly all of the country is susceptible to smoke and/or smog at least some of
More news about: Redfin
Aug 31, 2026, 06:00 ET IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer
for IDE849, a potential best-in-class delta-like ligand 3 (DLL3)-targeting Topo-I-payload antibody drug conjugate (ADC), in extensive stage small cell lung cancer (ES-SCLC). IDEAYA is targeting to initiate the Phase 3 registrational study in ES-SCLC by year-end 2026.
More news about: IDEAYA Biosciences, Inc.
Aug 28, 2026, 22:00 ET TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX
TransMedics is a medical technology company focused on transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure. The Company operates the Organ Care System, or OCS, and the National OCS Program, or NOP.On January 10, Scorpion Capital
More news about: Kahn Swick & Foti, LLC
Aug 28, 2026, 11:41 ET Orsini to Serve as Specialty Pharmacy Partner for Priovant's LISRAYA™ (brepocitinib)
autoimmune inflammatory disease characterized by painful skin rashes and debilitating muscle weakness, as well as broader systemic manifestations such as lung disease, cardiac disease and gastrointestinal complications. LISRAYA represents the first targeted treatment option approved for dermatomyositis. It
More news about: Orsini
Aug 28, 2026, 07:31 ET Asieris Pharmaceuticals Releases 2026 Semi-Annual Report: Core Product Commercialization Delivers, Entering a Harvest Period as the Company Accelerates Its Transition to Biopharma
start a Phase I monotherapy dose-escalation study by year-end enrolling patients with advanced solid tumors including ovarian cancer and non-small cell lung cancer. APL-2302 (USP1 inhibitor) is currently in an ongoing Phase I/IIa clinical trial for the treatment of advanced solid tumors.In other disease
More news about: Asieris
Aug 27, 2026, 23:52 ET JULIEN'S AUCTIONS THÔNG BÁO PHIÊN ĐẤU GIÁ "VUA QUÁI VẬT KAIJU: BỘ SƯU TẬP DI SẢN SOMPOTE SANDS"
Bay Thu Nhỏ Quảng Bá Ultraman, Tượng Thiết Kế, Mặt Nạ, Trang Phục Ghi Hình, Tượng Nhỏ, Tranh 3D Ultraman, Pigmon & Alien Baltan do Nhà Thiết Kế Lừng Danh Tohl Narita Thực Hiện, Tác Phẩm Vẽ Tay Áp Phích Nguyên Bản và Nhiều Kỷ Vật Khác từ các Bộ Phim Kinh Điển Như Hanuman và 5 Kỵ
More news about: Julien's Auctions
Aug 27, 2026, 22:44 ET Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's
Company's five self-commercialized innovative drugs had been included in China's National Reimbursement Drug List (NRDL). These include two non-small cell lung cancer (NSCLC) indications for ivonescimab (PD-1/VEGF bispecific antibody) and three cervical and gastric cancer indications for cadonilimab (PD-1/CTLA-4
More news about: Akeso, Inc.
Aug 27, 2026, 16:01 ET Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer
as we continue enrollment in the Phase 1b trial."Clinical responses were observed across a broad range of metastatic disease sites, including lung, liver, bone, lymph node and central nervous system target lesions, with responses emerging as early as approximately three months post-randomization.
More news about: Kazia Therapeutics Limited
Aug 27, 2026, 12:00 ET BioVid Launches Tumor Worlds™: A Strategic Intelligence System to Decode the Behavioral Logic of Oncology Markets
Worlds™ moves beyond descriptive market research to provide an early signal model of physician decision-making. The launch begins with Non-Small Cell Lung Cancer (NSCLC), with Prostate and Pancreatic Cancer to follow, and full portfolio expansion planned through 2026.
More news about: BioVid
Aug 27, 2026, 10:15 ET CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum
observed in both the objective response rate (ORR) and duration of response (DOR):Compelling monotherapy efficacy in first-line non-small cell lung cancer (NSCLC)At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease control rate (DCR) of 100%
More news about: CStone Pharmaceuticals
Aug 27, 2026, 08:30 ET Caris Life Sciences Publishes npj Precision Oncology Study Showing AI-Guided Therapy Selection is Predictive of Longer Survival in Patients with Pancreatic Cancer
relevant findings across all tumor types, with disease-specific algorithms to support treatment decision-making in colon, breast, ovarian, pancreatic and lung cancer.For patients with advanced pancreatic ductal adenocarcinoma (PDAC), first-line therapy options include FOLFIRINOX, gem/nab-p, and NALIRIFOX.
More news about: Caris Life Sciences
Aug 27, 2026, 07:02 ET Fosun International Reports 1H2026 Results: Total Revenue RMB86.96 Billion, Net Profit RMB1.72 Billion
has demonstrated preliminary clinical efficacy characterized by high efficacy and low toxicity across multiple solid tumors, including non-small cell lung cancer (NSCLC). To date, more than ten clinical studies of HLX43 as monotherapy or in combination regimens have been initiated, with over 1,500 patients
More news about: Fosun
Aug 27, 2026, 05:01 ET NYU Langone Health Names Sunil Rao, MD, Director of the Leon H. Charney Division of Cardiology and Welcomes Susheel Kodali, MD, to Lead Interventional Cardiology
approaches that allow physicians to treat blocked arteries through the wrist rather than traditional access points. He currently leads a National Heart, Lung, and Blood Institute–funded clinical trial studying treatments for patients with intermediate-risk pulmonary embolism, a serious condition caused by
More news about: NYU Langone Health